I do not entirely disagree, but it’s kind of a rational preservation of their ability to do their job in the best manner possible for the public without regard to the applicant.
DNDN was before the reforms and DNDN’s trial actually was flawed. I recall when they popped thinking for the only time (since I have invested in this sector) and quite seriously, about shorting the pop even though I knew they’d likely eventually get approved. My view was that investors had taken the wrong message from the FDA’s communication. But I don’t short. The money one could make was just so obvious. Their situation was obvious to anyone with regulatory experience.
This is a cellular treatment, so AMRN is not relevant, even though more recent.
I actually have experience with regulators. I have due respect for the process and procedures, even if many traders and bulletin board posters do not. I think there will be a rational and reasonable result.
News 
Market Data 
Discover 
